A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
NCT ID: NCT04261933
Last Updated: 2023-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
789 participants
OBSERVATIONAL
2020-02-13
2021-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
NCT04094415
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
NCT02060266
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
NCT05502562
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
NCT02255266
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
NCT01686945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Semaglutide s.c. once-weekly
Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
* Male or female, age 18 years or older at the time of signing informed consent
* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
* Available and documented haemoglobin A1c (HbA1c) value equal to or below 12 weeks prior to initiation of semaglutide treatment
Exclusion Criteria
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Treatment with any investigational drug within 90 days prior to enrolment into the study
* Hypersensitivity to semaglutide or to any of the excipients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor & Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Amberg, , Germany
Novo Nordisk Investigational Site
Aschaffenburg, , Germany
Novo Nordisk Investigational Site
Augsburg, , Germany
Novo Nordisk Investigational Site
Bad Mergentheim, , Germany
Novo Nordisk Investigational Site
Bad Oeynhausen, , Germany
Novo Nordisk Investigational Site
Bautzen, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Bernau bei Berlin, , Germany
Novo Nordisk Investigational Site
Bonn, , Germany
Novo Nordisk Investigational Site
Bramsche, , Germany
Novo Nordisk Investigational Site
Cologne, , Germany
Novo Nordisk Investigational Site
Cologne, , Germany
Novo Nordisk Investigational Site
Darmstadt, , Germany
Novo Nordisk Investigational Site
Dessau, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Duisburg, , Germany
Novo Nordisk Investigational Site
Eisenach, , Germany
Novo Nordisk Investigational Site
Elsterwerda, , Germany
Novo Nordisk Investigational Site
Erdmannhausen, , Germany
Novo Nordisk Investigational Site
Erlangen, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Forst, , Germany
Novo Nordisk Investigational Site
Freisen, , Germany
Novo Nordisk Investigational Site
Friedrichsthal, , Germany
Novo Nordisk Investigational Site
Fulda, , Germany
Novo Nordisk Investigational Site
Gebhardshain, , Germany
Novo Nordisk Investigational Site
Gelnhausen, , Germany
Novo Nordisk Investigational Site
Grasleben, , Germany
Novo Nordisk Investigational Site
Großröhrsdorf, , Germany
Novo Nordisk Investigational Site
Grünstadt, , Germany
Novo Nordisk Investigational Site
Hainburg, , Germany
Novo Nordisk Investigational Site
Halle, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Hammelburg, , Germany
Novo Nordisk Investigational Site
Hanover, , Germany
Novo Nordisk Investigational Site
Heidenheim, , Germany
Novo Nordisk Investigational Site
Herrenberg, , Germany
Novo Nordisk Investigational Site
Hof, , Germany
Novo Nordisk Investigational Site
Hohenmölsen, , Germany
Novo Nordisk Investigational Site
Jena, , Germany
Novo Nordisk Investigational Site
Kempten (Allgäu), , Germany
Novo Nordisk Investigational Site
Leipzig, , Germany
Novo Nordisk Investigational Site
Lichtenfels, , Germany
Novo Nordisk Investigational Site
Lingen, , Germany
Novo Nordisk Investigational Site
Ludwigsburg, , Germany
Novo Nordisk Investigational Site
Magdeburg, , Germany
Novo Nordisk Investigational Site
Marburg, , Germany
Novo Nordisk Investigational Site
Marburg, , Germany
Novo Nordisk Investigational Site
Mayen, , Germany
Novo Nordisk Investigational Site
Meckesheim, , Germany
Novo Nordisk Investigational Site
Mössingen, , Germany
Novo Nordisk Investigational Site
Mühldorf, , Germany
Novo Nordisk Investigational Site
Mülheim, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Münster, , Germany
Novo Nordisk Investigational Site
Neustrelitz, , Germany
Novo Nordisk Investigational Site
Nuremberg, , Germany
Novo Nordisk Investigational Site
Oranienburg, , Germany
Novo Nordisk Investigational Site
Osnabrück, , Germany
Novo Nordisk Investigational Site
Otterbach, , Germany
Novo Nordisk Investigational Site
Pohlheim, , Germany
Novo Nordisk Investigational Site
Rellingen, , Germany
Novo Nordisk Investigational Site
Rostock, , Germany
Novo Nordisk Investigational Site
Saint Ingbert-Oberwürzbach, , Germany
Novo Nordisk Investigational Site
Schorndorf, , Germany
Novo Nordisk Investigational Site
Schönhausen (Elbe), , Germany
Novo Nordisk Investigational Site
Schwerin, , Germany
Novo Nordisk Investigational Site
Seelow, , Germany
Novo Nordisk Investigational Site
Soltau, , Germany
Novo Nordisk Investigational Site
Sonsbeck, , Germany
Novo Nordisk Investigational Site
Speyer, , Germany
Novo Nordisk Investigational Site
Spremberg, , Germany
Novo Nordisk Investigational Site
Stadtbergen, , Germany
Novo Nordisk Investigational Site
Straubing, , Germany
Novo Nordisk Investigational Site
Stuttgart, , Germany
Novo Nordisk Investigational Site
Stuttgart, , Germany
Novo Nordisk Investigational Site
Trier, , Germany
Novo Nordisk Investigational Site
Ulm, , Germany
Novo Nordisk Investigational Site
Viersen, , Germany
Novo Nordisk Investigational Site
Villingen-Schwenningen, , Germany
Novo Nordisk Investigational Site
Villingen-Schwenningen, , Germany
Novo Nordisk Investigational Site
Wedemark, , Germany
Novo Nordisk Investigational Site
Wetzlar, , Germany
Novo Nordisk Investigational Site
Wiesloch, , Germany
Novo Nordisk Investigational Site
Witzenhausen, , Germany
Novo Nordisk Investigational Site
Wolmirstedt, , Germany
Novo Nordisk Investigational Site
Wurzen, , Germany
Novo Nordisk Investigational Site
Zwenkau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vilsboll T, Lindahl CO, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023 Jun;25(6):1740-1749. doi: 10.1111/dom.15031. Epub 2023 Mar 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1241-6291
Identifier Type: OTHER
Identifier Source: secondary_id
NN9535-4617
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.